Hyperlipoproteinemias - 25 Studies Found Completed : Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia : Hyperlipoproteinemia : 2013-03-10 : Drug: Coenzyme A Coenzyme A 40 Completed : The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia : Hyperlipoproteinemia : 2012-07-17 : Drug: Coenzyme A Coenzyme A 20 Recruiting : Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes : Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia : 2016-05-26 Recruiting : Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease : Elevated Lipoprotein(a) Cardiovascular Disease : 2017-01-31 : Drug: ISIS 681257 Randomly ass Completed : Lipoprotein Metabolism in Normal Volunteers and Patients With Abnormal Levels of Lipoproteins : Healthy Hyperlipoproteinemia : 1999-11-03 Withdrawn : Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a) : Hyperlipoproteinemia(a) Progressive Cardiovascular Disease : 2010-02-08 : Procedure: Lipid apheresis Wee Completed : A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin : Hypercholesterolemia Hyperlipoproteinemia : 2010-01-26 : Drug: Pravastatin Pravastatin Terminated : Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042) : Hyperlipoproteinemia Type II Homozygous Familial Hypercholester : 2013-04-24 : Drug: Anacetrapib 100 mg table Active, not recruiting : Study to Assess the Tolerability and Efficacy of Anacetrapib Co-administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) : Hyperlipoproteinemia Type II Heterozygous Familial Hypercholest : 2012-01-30 : Drug: Anacetrapib one 100 mg t Terminated : Effect of Niacin/Laropiprant on Postprandial Lipoprotein Metabolism in Patients With Dyslipoproteinemia : Hyperlipoproteinemia Metabolic Syndrome : 2010-11-12 : Drug: Niacin/ Laropiprant 1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily <<< Previous | Next >>>